Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a remote nurse boost HIV prevention at kenyan pharmacies?

NCT ID NCT07561658

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests whether adding a remote nurse via telehealth to pharmacy-based PrEP/PEP services helps more people start and continue HIV prevention. About 1,580 pharmacy clients in Kenya will either get standard pharmacy care or extra telehealth support with SMS reminders. The goal is to see if the telehealth approach increases medication use and is cost-effective.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Telehealth support (remote nurse counseling and SMS) alongside pharmacy-dispensed PrEP/PEP
What this could lead to
If successful, this could show that telehealth support makes HIV prevention medications more accessible and easier to stick with, potentially reducing new HIV infections.
What could go wrong
This is an early-stage implementation study, not a drug trial. Results may vary by pharmacy setting, and the added cost of telehealth may not be sustainable or effective everywhere.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 1,580 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Sep 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

15 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Pharmacies * Registered with the Pharmacy and Poisons Board (PPB) * Must have at least one full-time licensed pharmacist or pharmaceutical technologist on staff * Must have a private room where HIV testing and PrEP/PEP counseling can occur * \>3 km from other study pharmacies * Willing to participate in research activities, including 2-day training for pharmacy providers * Willing to share pharmacy records with us * Sells HIVST kits that are WHO certified. Pharmacists/remote nurses * ≥ 18 years old * Licensed pharmacist, pharmaceutical technologist, or nurse * Willing to provide PrEP and PEP services, including HIV testing and associated counseling services * Willing to complete training on PEP/PrEP service delivery at pharmacies, including certification for rapid diagnostic testing * Able and willing to provide informed consent Clients * ≥ 15 years old * Interested in being screened for PrEP or PEP * Meets all criteria to be eligible for pharmacy-delivered PrEP or PEP on the Prescribing Checklist, including being at risk for HIV and not having any medical conditions that might contraindicate PrEP/PEP safety * Able and willing to provide informed consent Exclusion Criteria: Clients * Unwilling to provide a phone number at which an RA can reach them for completing surveys and communicate important study-related information * Currently enrolled in any other HIV vaccine or prevention trial * Have a condition that would preclude provision of informed consent, make study participation unsafe, complicate interpretation of outcome data, or otherwise interfere with achieving study objectives

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Kenya Medical Research Institute

    Kisumu, Kenya

More trials for these conditions

Other studies related to the condition(s) this trial covers.